ARCHIVES

In this 12-page issue: Moonlighting by NCI and FDA scientists conflicted with CRADA work, House Subcommittee on Oversight and Investigations says.

This article is from The Cancer Letter archive.

Vol. 30 No. 21 | May 21, 2004

Download PDF Visit The Full Archive

Related Articles

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

May 6, 2005

Army of Women, caBIG To Collaborate.

August 7, 2009

Breast Cancer Vs. Other Cancers In Budget Showdown

July 3, 1992

Community Based Organizing Nearly Complete; Conn. Still Planning

November 25, 1977

More Clinical Trials Money Top Priority, DeVita Says; Drug Discovery Groups RFA Gets 12 Applications

February 24, 1984

Katterhagen Predicts Increase Support From State, Local sources, Sees It As Community Challenge

March 27, 1981